Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Fisher & Paykel Healthcare Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$14.23 billion
P/E Ratio
59.82
Dividend Yield
1.36%
Shares Outstanding
582.17 million
Earnings per share
0.449
Dividend per share
0.33
Year To Date Return
12.69%
Earnings Yield
1.67%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News
Share Fallers
These were the worst performers on the ASX 200 in April
⏸️ TMF AMP
Top ASX Stock Picks for May 2020
Share Market News
T. Rowe Price has been buying these ASX shares during the coronavirus crash
Growth Shares
3 top ASX growth shares to buy that just keep growing
Share Market News
RBA warns of 'difficult days' to come for Australian economy
Share Gainers
These ASX 200 shares are up over 30% in 2020 despite the coronavirus crash
Share Gainers
Why a2 Milk, Fisher & Paykel Healthcare, Star, & Starpharma are pushing higher
Share Market News
Business confidence down, ASX shares up?
Share Market News
Revealed: Which ASX shares will grow during coronavirus?
Coronavirus News
These ASX shares are thriving despite the bear market
⏸️ TMF AMP
ASX 200 Weekly Wrap: ASX has best week since GFC
Share Fallers
These were the worst performing ASX 200 shares last week
Frequently Asked Questions
-
Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.
-
Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.
-
Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.
-
Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.
-
Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 05 Dec 2023 | $0.0318 | 0.00% | Supplemental | 18 Dec 2023 |
| 05 Dec 2023 | $0.1800 | 0.00% | Interim | 18 Dec 2023 |
| 26 Jun 2023 | $0.0406 | 0.00% | Supplemental | 07 Jul 2023 |
| 26 Jun 2023 | $0.2117 | 0.00% | Interim | 07 Jul 2023 |
| 08 Dec 2022 | $0.0309 | 0.00% | Supplemental | 21 Dec 2022 |
| 08 Dec 2022 | $0.1645 | 0.00% | Interim | 21 Dec 2022 |
| 22 Jun 2022 | $0.0397 | 0.00% | Supplemental | 06 Jul 2022 |
| 22 Jun 2022 | $0.2029 | 0.00% | Final | 06 Jul 2022 |
| 02 Dec 2021 | $0.0300 | 0.00% | Supplemental | 15 Dec 2021 |
| 02 Dec 2021 | $0.1784 | 0.00% | Interim | 15 Dec 2021 |
| 24 Jun 2021 | $0.0388 | 0.00% | Supplemental | 07 Jul 2021 |
| 24 Jun 2021 | $0.2046 | 0.00% | Final | 07 Jul 2021 |
| 03 Dec 2020 | $0.0282 | 0.00% | Supplemental | 16 Dec 2020 |
| 03 Dec 2020 | $0.1510 | 0.00% | Interim | 16 Dec 2020 |
| 06 Jul 2020 | $0.0274 | 0.00% | Supplemental | 17 Jul 2020 |
| 06 Jul 2020 | $0.1463 | 0.00% | Final | 17 Jul 2020 |
| 06 Dec 2019 | $0.0212 | 0.00% | Supplemental | 19 Dec 2019 |
| 06 Dec 2019 | $0.1148 | 0.00% | Interim | 19 Dec 2019 |
| 13 Jun 2019 | $0.1287 | 0.00% | Final | 05 Jul 2019 |
| 07 Dec 2018 | $0.0172 | 0.00% | Supplemental | 21 Dec 2018 |
| 07 Dec 2018 | $0.0921 | 0.00% | Interim | 21 Dec 2018 |
| 21 Jun 2018 | $0.0221 | 0.00% | Supplemental | 06 Jul 2018 |
| 21 Jun 2018 | $0.1151 | 0.00% | Final | 06 Jul 2018 |
| 05 Dec 2017 | $0.0154 | 0.00% | Supplemental | 20 Dec 2017 |
| 05 Dec 2017 | $0.7802 | 0.00% | Interim | 20 Dec 2017 |
| 15 Jun 2017 | $0.0199 | 0.00% | Supplemental | 07 Jul 2017 |
| 15 Jun 2017 | $0.1074 | 0.00% | Final | 07 Jul 2017 |
| 06 Dec 2016 | $0.0789 | 0.00% | Interim | 21 Dec 2016 |
| 16 Jun 2016 | $0.0955 | 0.00% | Final | 08 Jul 2016 |
| 09 Dec 2015 | $0.0629 | 0.00% | Interim | 23 Dec 2015 |
| 17 Jun 2015 | $0.0710 | 0.00% | Final | 10 Jul 2015 |
| 03 Dec 2014 | $0.0537 | 0.00% | Interim | 19 Dec 2014 |
| 18 Jun 2014 | $0.0650 | 0.00% | Final | 04 Jul 2014 |
| 04 Dec 2013 | $0.0491 | 0.00% | Interim | 19 Dec 2013 |
| 19 Jun 2013 | $0.0586 | 0.00% | Final | 05 Jul 2013 |
| 29 Nov 2012 | $0.0426 | 0.00% | Interim | 14 Dec 2012 |
| 20 Jun 2012 | $0.0550 | 0.00% | Final | 06 Jul 2012 |
| 30 Nov 2011 | $0.0413 | 0.00% | Interim | 16 Dec 2011 |
| 22 Jun 2011 | $0.0534 | 0.00% | Final | 08 Jul 2011 |
| 01 Dec 2010 | $0.0418 | 0.00% | Interim | 17 Dec 2010 |
| 28 Jun 2010 | $0.0000 | 0.00% | Final | 09 Jul 2010 |
| 10 Dec 2009 | $0.0301 | 0.00% | Interim | 18 Dec 2009 |
| 22 Jun 2009 | $0.0476 | 0.00% | Final | 06 Jul 2009 |
| 04 Dec 2008 | $0.0095 | 0.00% | Supplemental | 12 Dec 2008 |
| 04 Dec 2008 | $0.0000 | 0.00% | Interim | 12 Dec 2008 |
| 19 Jun 2008 | $0.0062 | 0.00% | Supplemental | 27 Jun 2008 |
| 19 Jun 2008 | $0.0700 | 0.00% | Final | 27 Jun 2008 |
| 06 Dec 2007 | $0.0095 | 0.00% | Supplemental | 14 Dec 2007 |
| 06 Dec 2007 | $0.0473 | 0.00% | Interim | 14 Dec 2007 |
| 21 Jun 2007 | $0.0124 | 0.00% | Supplemental | 29 Jun 2007 |
| 21 Jun 2007 | $0.0700 | 0.00% | Final | 29 Jun 2007 |
| 23 Nov 2006 | $0.0095 | 0.00% | Supplemental | 01 Dec 2006 |
| 23 Nov 2006 | $0.0540 | 0.00% | Interim | 01 Dec 2006 |
| 19 Jun 2006 | $0.0124 | 0.00% | Supplemental | 28 Jun 2006 |
| 19 Jun 2006 | $0.0700 | 0.00% | Final | 28 Jun 2006 |
| 02 Dec 2005 | $0.0095 | 0.00% | Supplemental | 09 Dec 2005 |
| 02 Dec 2005 | $0.0540 | 0.00% | Interim | 09 Dec 2005 |
| 08 Jun 2005 | $0.0102 | 0.00% | Supplemental | 17 Jun 2005 |
| 08 Jun 2005 | $0.0580 | 0.00% | Final | 17 Jun 2005 |
| 24 Nov 2004 | $0.0088 | 0.00% | Supplemental | 03 Dec 2004 |
| 24 Nov 2004 | $0.0500 | 0.00% | Interim | 03 Dec 2004 |
| 14 Jun 2004 | $0.0494 | 0.00% | Supplemental | 18 Jun 2004 |
| 14 Jun 2004 | $0.2800 | 0.00% | Final | 18 Jun 2004 |
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.
The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.
Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico.
FPH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Apr 2024 | $24.37 | $-0.23 | -0.93% | 285,168 | $23.93 | $24.52 | $23.87 |
| 17 Apr 2024 | $24.60 | $0.46 | 1.91% | 204,035 | $24.08 | $24.63 | $23.97 |
| 16 Apr 2024 | $24.14 | $-0.20 | -0.82% | 574,005 | $23.97 | $24.29 | $23.97 |
| 15 Apr 2024 | $24.34 | $0.26 | 1.08% | 317,301 | $23.86 | $24.45 | $23.79 |
| 12 Apr 2024 | $24.08 | $-0.06 | -0.25% | 139,545 | $23.13 | $24.17 | $23.13 |
| 11 Apr 2024 | $24.14 | $-0.08 | -0.33% | 272,214 | $23.82 | $24.18 | $23.75 |
| 10 Apr 2024 | $24.22 | $0.59 | 2.50% | 325,941 | $23.65 | $24.31 | $23.65 |
| 09 Apr 2024 | $23.63 | $0.18 | 0.77% | 183,060 | $23.45 | $23.65 | $23.19 |
| 08 Apr 2024 | $23.45 | $-0.27 | -1.14% | 243,464 | $23.63 | $23.79 | $23.27 |
| 05 Apr 2024 | $23.72 | $0.45 | 1.93% | 334,345 | $22.94 | $23.88 | $22.94 |
| 04 Apr 2024 | $23.27 | $0.07 | 0.30% | 215,487 | $23.33 | $23.34 | $23.00 |
| 03 Apr 2024 | $23.20 | $-0.63 | -2.64% | 315,068 | $23.29 | $23.45 | $23.02 |
| 02 Apr 2024 | $23.83 | $0.17 | 0.72% | 443,605 | $23.65 | $24.00 | $23.40 |
| 28 Mar 2024 | $23.66 | $-0.67 | -2.75% | 871,671 | $23.87 | $24.31 | $23.19 |
| 27 Mar 2024 | $24.33 | $-0.03 | -0.12% | 282,057 | $24.25 | $24.42 | $24.14 |
| 26 Mar 2024 | $24.36 | $0.31 | 1.29% | 541,693 | $24.10 | $24.50 | $23.88 |
| 25 Mar 2024 | $24.05 | $-0.13 | -0.54% | 498,976 | $24.20 | $24.77 | $24.05 |
| 22 Mar 2024 | $24.18 | $1.73 | 7.71% | 757,964 | $23.60 | $24.24 | $23.49 |
| 21 Mar 2024 | $22.45 | $0.25 | 1.13% | 379,615 | $22.35 | $22.76 | $22.15 |
| 20 Mar 2024 | $22.20 | $0.00 | 0.00% | 306,755 | $22.17 | $22.24 | $21.88 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from November 2001 to March 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company.
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon became Managing Director & Chief Executive Officer in April 2016. Prior to that, he spent 15 years as Senior Vice President - Products & Technology, and six years as General Manager - Research and Development. During his 38-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive Director | Nov 2018 |
-
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Oct 2021 |
Ms McIntyre is a director of HCF Group, The University of Sydney, Studiosity, and Nanosonics. In addition to her current directorships, she has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. She spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia.
|
| Mr Donal Paul O'Dwyer | Non-Executive Director | Dec 2012 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a nonexecutive director of Sonic Healthcare and Q'Biotics Group and a former director of The Board of Tax, South East Sydney Local Health District, Osprey Medical and Sirtex Limited. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission.
|
| Ms Geraldine Celia McBride | Non-Executive Director | Aug 2013 |
Ms McBride has been involved in the technology industry for 30 years and has a wealth of global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of Sky Network Television Ltd and the founder and CEO of MyWave.
|
| Mr Scott Andrew St John | Non-Executive DirectorNon-Executive Chairman | Oct 2015 |
Mr John is director of ANZ New Zealand Bank Limited, Mercury Limited, the NEXT Foundation and Fonterra Cooperative Group Limited. Scott was Chief Executive Officer of First NZ Capital from 2002 to 2017. He previously served as the Chancellor of the University of Auckland, Chairman of the Securities Industries Association and was a member of the Financial Markets Authority Establishment Board.
|
| Ms Philippa (Pip) Mary Greenwood | Non-Executive Director | Jun 2017 |
Mr Greenwood is chair of Westpac New Zealand Limited, a director of a2 Milk Company Limited and Vulcan Steel Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011.
|
| Dr Cather Simpson | Non-Executive Director | Jun 2022 |
Dr Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, an early-stage investment company. She is a director of the International Society for Optics & Photonics (SPIE) and founder/director for Orbis Diagnostics. Dr Simpson also serves on the advisory boards of the Paihau-Robinson Research Institute at Victoria University and the New Zealand Product Accelerator.
|
| Mr Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
|
| Lyndal York | Chief Financial Officer |
-
|
|
| Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
|
| Paul Shearer | Senior Vice President - Sales & Marketing |
-
|
|
| Marcus Driller | Vice President - Corporate |
-
|
|
| Nicola Talbot | Vice President - Human Resources |
-
|
|
| Nicholas Fourie | Vice President - Information & Communication Technology |
-
|
|
| Dr Andrew Somervell | Vice President - Products & Technology |
-
|
|
| Brian Schultz | Vice President - Quality & Regulatory Affairs |
-
|
|
| Jonti Rhodes | Vice President - Supply Chain Facilities & Sustainability |
-
|
|
| Winston Fong | Vice President - Surgical Technologies |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Nominees (New Zealand) Limited R601127393 | 78,877,291 | 13.60% |
| HSBC Nominees (New Zealand) Limited R601127385 | 55,718,994 | 9.60% |
| HSBC Custody Nominees (Australia) Limited | 46,955,753 | 8.10% |
| JPMorgan Chase Bank | 39,490,847 | 6.80% |
| JPMorgan Nominees Australia Pty Limited | 34,669,791 | 6.00% |
| Citicorp Nominees Pty Limited | 34,071,336 | 5.90% |
| BNP Paribas Nominees NZ Limited Bpss40 | 28,584,162 | 4.90% |
| Citibank Nominees (NZ) Ltd | 25,912,512 | 4.50% |
| Custodial Services Limited | 21,213,545 | 3.70% |
| Tea Custodians Limited | 15,341,886 | 2.70% |
| New Zealand Superannuation Fund Nominees Limited | 12,830,044 | 2.20% |
| National Nominees Limited | 10,530,010 | 1.80% |
| Accident Compensation Corporation | 9,144,701 | 1.60% |
| Premier Nominees Limited | 7,950,251 | 1.40% |
| FNZ Custodians Limited | 7,519,717 | 1.30% |
| National Nominees New Zealand Limited | 6,591,985 | 1.10% |
| New Zealand Depository Nominee | 5,695,871 | 1.00% |
| JBWere (NZ) Nominees Limited | 5,402,872 | 0.90% |
| BNP Paribas Nominees NZ Limited | 5,034,091 | 0.90% |
| Public Trust | 4,724,236 | 0.80% |
